VistaGen Therapeutics (NASDAQ:VTGN) Releases Quarterly Earnings Results, Misses Estimates By $0.03 EPS

VistaGen Therapeutics (NASDAQ:VTGN) released its quarterly earnings results on Monday. The company reported ($0.37) EPS for the quarter, missing the consensus estimate of ($0.34) by ($0.03), FiscalAI reports. The company had revenue of $0.38 million for the quarter, compared to analysts’ expectations of $0.40 million.

VistaGen Therapeutics Stock Performance

NASDAQ:VTGN traded down $0.00 during mid-day trading on Monday, hitting $0.57. 1,020,450 shares of the company’s stock traded hands, compared to its average volume of 895,989. VistaGen Therapeutics has a 1 year low of $0.43 and a 1 year high of $5.14. The company has a market cap of $22.70 million, a PE ratio of -0.30 and a beta of 0.31. The firm’s 50 day simple moving average is $0.60 and its 200 day simple moving average is $1.03.

Analyst Ratings Changes

Several analysts recently commented on the stock. Wall Street Zen downgraded shares of VistaGen Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, March 21st. Weiss Ratings restated a “sell (e+)” rating on shares of VistaGen Therapeutics in a research report on Wednesday, June 3rd. Four research analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Reduce” and a consensus price target of $0.95.

Institutional Investors Weigh In On VistaGen Therapeutics

Several hedge funds have recently modified their holdings of the company. Virtu Financial LLC purchased a new position in shares of VistaGen Therapeutics during the 4th quarter worth about $25,000. Tudor Investment Corp ET AL purchased a new position in shares of VistaGen Therapeutics during the 4th quarter worth about $50,000. Millennium Management LLC lifted its holdings in shares of VistaGen Therapeutics by 853.0% during the 4th quarter. Millennium Management LLC now owns 197,045 shares of the company’s stock worth $130,000 after acquiring an additional 176,369 shares during the period. Luminus Management LLC purchased a new position in shares of VistaGen Therapeutics during the 4th quarter worth about $232,000. Finally, OMERS ADMINISTRATION Corp purchased a new position in shares of VistaGen Therapeutics during the 4th quarter worth about $68,000. 78.39% of the stock is owned by institutional investors and hedge funds.

VistaGen Therapeutics Company Profile

VistaGen Therapeutics, Inc (NASDAQ:VTGN) is a clinical-stage biopharmaceutical company dedicated to the discovery and development of next-generation medicines for central nervous system disorders. Incorporated in Delaware in 1998 and headquartered in South San Francisco, California, VistaGen applies advanced human pluripotent stem cell technologies to accelerate drug candidate validation and optimization. The company’s core focus is on addressing unmet medical needs in major depressive disorder, neuropathic pain and dermatological conditions.

The company’s lead candidate, AV-101, is an oral prodrug designed to modulate glutamatergic neurotransmission via the N-methyl-D-aspartate (NMDA) receptor pathway, with clinical programs targeting major depressive disorder and neuropathic pain.